Vertex Pharmaceuticals Incorporated VRTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.85% | 13.24% | 8.21% | 9.55% | 10.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.85% | 12.45% | 7.82% | 9.55% | 10.99% |
| Cost of Revenue | 13.16% | 7.01% | 0.87% | 1.24% | 9.78% |
| Gross Profit | 10.75% | 17.23% | 14.36% | 17.48% | 12.01% |
| SG&A Expenses | 44.04% | 37.12% | 24.55% | 28.97% | 19.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.64% | 14.07% | 6.27% | 7.06% | 12.03% |
| Operating Income | -1.20% | 9.92% | 10.45% | 13.58% | 9.47% |
| Income Before Tax | -39.68% | 8.48% | 71.54% | 17.11% | 6.10% |
| Income Tax Expenses | -39.88% | 16.75% | 163.38% | -37.40% | 20.82% |
| Earnings from Continuing Operations | -39.64% | 6.48% | 59.59% | 30.46% | 3.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.64% | 6.48% | 59.59% | 30.46% | 3.59% |
| EBIT | -1.20% | 9.92% | 10.45% | 13.58% | 9.47% |
| EBITDA | 0.02% | 9.89% | 10.67% | 13.60% | 9.12% |
| EPS Basic | -39.14% | 7.73% | 61.34% | 32.31% | 4.56% |
| Normalized Basic EPS | -3.69% | 12.44% | 10.22% | 14.84% | 10.43% |
| EPS Diluted | -39.05% | 8.02% | 61.45% | 32.87% | 4.74% |
| Normalized Diluted EPS | -3.59% | 12.74% | 10.38% | 15.18% | 10.85% |
| Average Basic Shares Outstanding | -0.82% | -1.17% | -1.09% | -1.40% | -0.93% |
| Average Diluted Shares Outstanding | -0.93% | -1.43% | -1.23% | -1.69% | -1.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |